News
Phase 3 trial opens in China for a new ovarian cancer maintenance treatment
AI-assisted summary Written by WellCareChina with AI assistance and checked against the original article.
AstraZeneca has registered a phase 3 trial, first posted on 1 October 2026, of torvutatug samrotecan plus bevacizumab against bevacizumab alone as first-line maintenance in advanced epithelial ovarian cancer without homologous recombination deficiency (HRD-negative). The study plans to enrol about 950 participants across 36 sites in China, according to the registry record, and its primary aim is efficacy, safety and tolerability. No results are posted yet.
Read the original article Opens the original source in a new tab.
Copyright and re-use
The original article is the authoritative text. This page carries our own summary and a link back; no part of the original is reproduced here.
Source tier A — trial registry record (public domain in the United States); our own summary and a link to the registry record, data as posted on 6 October 2026.